Abstract
Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 589-595 |
| Number of pages | 7 |
| Journal | Expert Opinion on Drug Discovery |
| Volume | 6 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- catechins
- drug discovery
- green tea
- insulin
- polyphenols
ASJC Scopus subject areas
- Drug Discovery
Cite this
Green tea polyphenols in drug discovery : A success or failure? / Smith, Thomas.
In: Expert Opinion on Drug Discovery, Vol. 6, No. 6, 06.2011, p. 589-595.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Green tea polyphenols in drug discovery
T2 - A success or failure?
AU - Smith, Thomas
PY - 2011/6
Y1 - 2011/6
N2 - Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.
AB - Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.
KW - catechins
KW - drug discovery
KW - green tea
KW - insulin
KW - polyphenols
UR - http://www.scopus.com/inward/record.url?scp=79957542707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957542707&partnerID=8YFLogxK
U2 - 10.1517/17460441.2011.570750
DO - 10.1517/17460441.2011.570750
M3 - Article
VL - 6
SP - 589
EP - 595
JO - Expert Opinion on Drug Discovery
JF - Expert Opinion on Drug Discovery
SN - 1746-0441
IS - 6
ER -